{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:03Z","timestamp":1761894723103},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11899-008-0015-9","type":"journal-article","created":{"date-parts":[[2008,4,28]],"date-time":"2008-04-28T07:17:42Z","timestamp":1209367062000},"page":"99-106","source":"Crossref","is-referenced-by-count":3,"title":["Role of allogeneic stem cell transplantation in multiple myeloma"],"prefix":"10.1007","volume":"3","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,29]]},"reference":[{"key":"15_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A. Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43\u201366.","journal-title":"CA Cancer J Clin"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832\u20133842.","journal-title":"J Clin Oncol"},{"key":"15_CR3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"8","author":"T.J. McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 8:822\u2013824.","journal-title":"Lancet"},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","volume":"70","author":"B. Barlogie","year":"1987","unstructured":"Barlogie B, Alexanian R, Dicke KA, et al.: High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987, 70:869\u2013872.","journal-title":"Blood"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M. Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91\u201397.","journal-title":"N Engl J Med"},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"J.A. Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875\u20131883.","journal-title":"N Engl J Med"},{"key":"15_CR7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M. Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495\u20132502.","journal-title":"N Engl J Med"},{"key":"15_CR8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ejca.2006.04.004","volume":"42","author":"S. Kumar","year":"2006","unstructured":"Kumar S, Rajkumar SV: Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006, 42:1612\u20131622.","journal-title":"Eur J Cancer"},{"key":"15_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"S.V. Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431\u2013436.","journal-title":"J Clin Oncol"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"S.V. Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, et al.: Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050\u20134053.","journal-title":"Blood"},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S. Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565\u20131571.","journal-title":"N Engl J Med"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"P.G. Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487\u20132498.","journal-title":"N Engl J Med"},{"key":"15_CR13","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 2007 [Epub ahead of print].","DOI":"10.1182\/blood-2007-10-116129"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","volume":"23","author":"P.L. Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333\u20136338.","journal-title":"J Clin Oncol"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","volume":"82","author":"A. Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA, et al.: Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323\u2013341.","journal-title":"Mayo Clin Proc"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G. Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, et al.: Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196\u20131198.","journal-title":"Blood"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","volume":"32","author":"E. Alyea","year":"2003","unstructured":"Alyea E, Weller E, Schlossman R, et al.: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003, 32:1145\u20131151.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1083-8791(03)00075-2","volume":"9","author":"C.A. Huff","year":"2003","unstructured":"Huff CA, Fuchs EJ, Noga SJ, et al.: Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 2003, 9:312\u2013319.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR19","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","volume":"90","author":"H.M. Lokhorst","year":"1997","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206\u20134211.","journal-title":"Blood"},{"key":"15_CR20","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","volume":"18","author":"G. Martinelli","year":"2000","unstructured":"Martinelli G, Terragna C, Zamagni E, et al.: Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000, 18:2273\u20132281.","journal-title":"J Clin Oncol"},{"key":"15_CR21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","volume":"98","author":"E. Alyea","year":"2001","unstructured":"Alyea E, Weller E, Schlossman R, et al.: T-cell\u2014depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001, 98:934\u2013939.","journal-title":"Blood"},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","volume":"105","author":"C. Crawley","year":"2005","unstructured":"Crawley C, Lalancette M, Szydlo R, et al.: Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532\u20134539.","journal-title":"Blood"},{"key":"15_CR23","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","volume":"97","author":"A. Badros","year":"2001","unstructured":"Badros A, Barlogie B, Morris C, et al.: High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97:2574\u20132579.","journal-title":"Blood"},{"key":"15_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","volume":"9","author":"K.S. Peggs","year":"2003","unstructured":"Peggs KS, Mackinnon S, Williams CD, et al.: Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003, 9:257\u2013265.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR25","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","volume":"103","author":"H.M. Lokhorst","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF, et al.: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103:4362\u20134364.","journal-title":"Blood"},{"key":"15_CR26","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","volume":"88","author":"W.I. Bensinger","year":"1996","unstructured":"Bensinger WI, Buckner CD, Anasetti C, et al.: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787\u20132793.","journal-title":"Blood"},{"key":"15_CR27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.2004.05330.x","volume":"128","author":"H.M. Hunter","year":"2005","unstructured":"Hunter HM, Peggs K, Powles R, et al.: Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning\u2014evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005, 128:496\u2013502.","journal-title":"Br J Haematol"},{"key":"15_CR28","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2003.04.033","volume":"21","author":"H.M. Lokhorst","year":"2003","unstructured":"Lokhorst HM, Segeren CM, Verdonck LF, et al.: Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003, 21:1728\u20131733.","journal-title":"J Clin Oncol"},{"key":"15_CR29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.bmt.1704868","volume":"35","author":"K.K. Ballen","year":"2005","unstructured":"Ballen KK, King R, Carston M, et al.: Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005, 35:675\u2013681.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"B.B. Bjorkstrand","year":"1996","unstructured":"Bjorkstrand BB, Ljungman P, Svensson H, et al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711\u20134718.","journal-title":"Blood"},{"key":"15_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G. Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, et al.: Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u20138 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209\u2013216.","journal-title":"Br J Haematol"},{"key":"15_CR32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","volume":"30","author":"S. Giralt","year":"2002","unstructured":"Giralt S, Aleman A, Anagnostopoulos A, et al.: Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002, 30:367\u2013373.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR33","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"D.G. Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, et al.: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447\u20133454.","journal-title":"Blood"},{"key":"15_CR34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"N. Kroger","year":"2002","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755\u2013760.","journal-title":"Blood"},{"key":"15_CR35","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","volume":"100","author":"N. Kroger","year":"2002","unstructured":"Kroger N, Sayer HG, Schwerdtfeger R, et al.: Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100:3919\u20133924.","journal-title":"Blood"},{"key":"15_CR36","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","volume":"109","author":"C. Crawley","year":"2007","unstructured":"Crawley C, Iacobelli S, Bjorkstrand B, et al.: Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007, 109:3588\u20133594.","journal-title":"Blood"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbmt.2006.11.011","volume":"13","author":"G.E. Georges","year":"2007","unstructured":"Georges GE, Maris MB, Maloney DG, et al.: Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007, 13:423\u2013432.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2007.00816.x","volume":"78","author":"B. Bruno","year":"2007","unstructured":"Bruno B, Sorasio R, Patriarca F, et al.: Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 2007, 78:330\u2013337.","journal-title":"Eur J Haematol"},{"key":"15_CR39","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F. Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, et al.: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474\u20133480.","journal-title":"Blood"},{"key":"15_CR40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B. Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, et al.: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110\u20131120.","journal-title":"N Engl J Med"},{"key":"15_CR41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","volume":"26","author":"M. Salama","year":"2000","unstructured":"Salama M, Nevill T, Marcellus D, et al.: Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000, 26:1179\u20131184.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR42","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","volume":"18","author":"H.M. Lokhorst","year":"2000","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031\u20133037.","journal-title":"J Clin Oncol"},{"key":"15_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1705742","volume":"40","author":"H. Levenga","year":"2007","unstructured":"Levenga H, Levison-Keating S, Schattenberg AV, et al.: Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant 2007, 40:355\u2013359.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR44","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","volume":"103","author":"K.S. Peggs","year":"2004","unstructured":"Peggs KS, Thomson K, Hart DP, et al.: Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548\u20131556.","journal-title":"Blood"},{"key":"15_CR45","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bmt.1704968","volume":"35","author":"M. Arora","year":"2005","unstructured":"Arora M, McGlave PB, Burns LJ, et al.: Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005, 35:1133\u20131140.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1701574","volume":"23","author":"H.M. Lokhorst","year":"1999","unstructured":"Lokhorst HM, Sonneveld P, Cornelissen JJ, et al.: Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 1999, 23:317\u2013322.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00000421-199710000-00005","volume":"20","author":"M. Varterasian","year":"1997","unstructured":"Varterasian M, Janakiraman N, Karanes C, et al.: Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol 1997, 20:462\u2013466.","journal-title":"Am J Clin Oncol"},{"key":"15_CR48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.bmt.1700738","volume":"19","author":"S. Couban","year":"1997","unstructured":"Couban S, Stewart AK, Loach D, et al.: Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 1997, 19:783\u2013789.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1703006","volume":"27","author":"C. Reynolds","year":"2001","unstructured":"Reynolds C, Ratanatharathorn V, Adams P, et al.: Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001, 27:801\u2013807.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR50","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2007.04.006","volume":"13","author":"J. Kuruvilla","year":"2007","unstructured":"Kuruvilla J, Shepherd JD, Sutherland HJ, et al.: Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007, 13:925\u2013931.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","volume":"121","author":"J.A. Perez-Simon","year":"2003","unstructured":"Perez-Simon JA, Martino R, Alegre A, et al.: Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003, 121:104\u2013108.","journal-title":"Br J Haematol"},{"key":"15_CR52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","volume":"36","author":"S. Gerull","year":"2005","unstructured":"Gerull S, Goerner M, Benner A, et al.: Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005, 36:963\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"15_CR53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/10428190601186150","volume":"48","author":"I. Majolino","year":"2007","unstructured":"Majolino I, Davoli M, Carnevalli E, et al.: Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007, 48:759\u2013766.","journal-title":"Leuk Lymphoma"},{"key":"15_CR54","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1532\/IJH97.04174","volume":"81","author":"C. Shimazaki","year":"2005","unstructured":"Shimazaki C, Fujii H, Yoshida T, et al.: Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group. Int J Hematol 2005, 81:342\u2013348.","journal-title":"Int J Hematol"},{"key":"15_CR55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bmt.1704531","volume":"34","author":"M. Mohty","year":"2004","unstructured":"Mohty M, Boiron JM, Damaj G, et al.: Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:77\u201384.","journal-title":"Bone Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0015-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0015-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T20:40:05Z","timestamp":1588624805000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0015-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0015-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}